Arkolith/Insider Trading/CTMX/Form 4

Ogden Christopher

Chief Financial OfficerCytomX Therapeutics, Inc. (CTMX) · full profile →Form 4 · filed Jun 17, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$5K
Net Open-Market Flow
-$5K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 15, 2026Sell(S)2K$3.05$5K295K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-26-000229) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML